INDIANAPOLIS (April 22, 2009) – OBS Medical’s BioQT™ technology has been recognized as a top finalist for the prestigious TechPoint Mira Award “Healthcare IT Innovation Award”. Now in its 10th year, the 2009 Mira Awards presented by BKD represents the top technology businesses, business professionals and educators in the state of Indiana. BKD is the CPA and advisory firm of choice for growing companies and is one of the ten largest such firms in the United States. The winner will be announced at an awards banquet on May 16.
“To receive a record number of entries into the Mira Awards competition and to see so many technology-related companies thriving—particularly during the current national economic downturn—is a real testament to the strength of Indiana’s tech sector,” said Jim Jay, president and CEO of TechPoint. “The Mira Awards recognize the achievements of some outstanding performers and contributors.”
OBS Medical provides innovative clinical algorithms such as BioQT, an advanced signal processing technique. BioQT generates an efficient and accurate measurement of ECG QT interval, T wave morphology and other cardiac safety parameters assessed during drug trials.; It is a thorough and efficient way to produce accurate cardiac safety profiles for new and existing drugs. OBS Medical recently conducted an industry-first cardiac safety study in which BioQT high-throughput analytical platform was used to prospectively analyze QT and T wave morphology changes for a drug compound. BioQT data was among the information used by the FDA to allow the drug to move into its next phase of development.
Consulting Chief Medical Officer Jay W. Mason, M.D. has been instrumental in the development and refinement of BioQT. As a result, OBS Medical is poised to take its cardiac safety solutions to the next level. OBS Medical will be participating in the upcoming DIA conferences – “Cardiovascular Safety, QT and Arrhythmia in Drug Development” in Bethesda and the 45th Annual Meeting in San Diego. Dr. Mason will present during a session regarding “Automated ECG Analysis” on April 30 in Bethesda.
“We are honored to be recognized by the respected Mira Awards,” says OBS Medical’s Chief Operating Officer, Wayne Nethercutt. To be recognized a second time for another OBS patient safety algorithm technology demonstrates the abilities of the R&D team through their collaborative work with Oxford University to develop influential medical technologies. In 2007, the Visensia® hospital patient safety technology was also recognized by the Mira Awards and OBS Medical was named a top finalist for the “Health & Life Sciences Gazelle Company Award”. “We are very pleased by the clinical and scientific recognition our BioQT and Visensia patient safety technologies have received. Our recent organization changes enable us to focus on commercialization activities for our current products in the US while our R&D team continues to enhance these products and develop new algorithm technologies with Oxford University in the UK,” says Nethercutt.
About OBS Medical
OBS Medical is based in Carmel, Indiana and provides innovative clinical algorithms for safer hospitals, safer patients and safer drugs. Based on intelligent algorithms such as neural networks, data fusion and ECG waveform recognition, OBS Medical technologies cover a range of medical applications including automated early crisis warning (Visensia®), automated assessment of ECG waveforms including QT interval measurement and morphology tracking (BioQT™), and EEG analysis for brain-state assessment. OBS Medical is a wholly-owned subsidiary of Oxford BioSignals Ltd. based in Oxford, UK, which was originally spun out from Oxford University.
Contact: